AbbVie Acquires Apogee Therapeutics for $10.9 Billion

SentiSense · Published · Updated

AbbVie has agreed to purchase Apogee Therapeutics in a $10.9 billion deal. The acquisition aims to expand AbbVie's immunology portfolio with Apogee's ...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis